Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
ZYME Stock — Zymeworks Inc.
Zymeworks Inc. (ZYME)
Updated October 16, 2026.
ZYME is a Stock. Total return is 92.5% over the past 9.5 years, 179.1 points behind SPY at 271.6%.
Zymeworks Inc. is a biotechnology company developing biotherapeutics for cancer, inflammation, and autoimmune diseases using proprietary platforms including multispecific antibodies, antibody-drug conjugates, and immune co-stimulation technologies. The company has multiple product candidates in clinical development, including lead programs targeting HER2-expressing tumors and prostate cancer, alongside strategic partnerships with major pharmaceutical companies. Zymeworks does not currently pay distributions.
ZYME performance versus SPY
Price and return data through 2026-10-16.
Total return is 92.5% over the past 9.5 years, 179.1 points behind SPY at 271.6%. Over the past year its total return — price change plus distributions reinvested — is 34.9%. Its deepest 1-year drawdown was 23.6%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -4.6% | — |
| 3M | 3.5% | — |
| 6M | -8.0% | — |
| YTD | -4.9% | — |
| 1Y | 34.9% | — |
| 2Y CAGR | — | 36.20% |
| 3Y CAGR | — | 52.50% |
| 5Y CAGR | — | -0.70% |
| Since inception (9.5 years) | 92.5% | 7.20% |
ZYME key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 04/28/2017
- Distribution frequency
- None
- Last close
- $25.03 (as of 2026-10-16)
- Market cap
- $1,782,136,000
- Average volume
- 631860.0
- Beta
- 1.173
- Payout ratio
- 0.0%
- Forward P/E
- 20.8333
- EPS
- $-2.00
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
ZYME risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 23.6%.
Who may consider ZYME — and who may not
It is a weaker fit for investors who need monthly cash flow (ZYME does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on ZYME
Frequently asked questions
Does ZYME pay monthly?
No. ZYME does not currently distribute.
When does ZYME pay a dividend?
ZYME does not currently distribute.
How has ZYME performed?
Total return is 92.5% over the past 9.5 years, 179.1 points behind SPY at 271.6%. Over the past year its total return — price change plus distributions reinvested — is 34.9%. Its deepest 1-year drawdown was 23.6%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.